
Pipeline Database
UB552
Compound Potassium Hydrogen Phosphate Injection
UB552
ProductCompound Potassium Hydrogen Phosphate Injection
Strength5ml containing 1.2g potassium dihydrogen phosphate and 1.18g dipotassium hydrogen phosphate (as K₂HPO₄)
IndicationsHypophosphataemia; Parenteral nutrition
TherapeuticsGastroenterology & Hepatology
GMPCN - NMPA
RegistrationChina
ModalitiesSmall Molecule
Exclusive Summary
- Stable and global demand for phosphate supplements, with broad market appeal as an essential medicine.
- In-house raw material production and bioequivalence approval ensure high quality and controlled costs, providing a significant competitive edge in the global generics market.
- Mature formulation and well-established clinical status offer wide potential distribution markets.
- The generic market for this product is relatively fragmented, presenting opportunities for new entrants globally.
- Chinese manufacturing expertise and cost-efficiency make it highly competitive, especially in low- and middle-income countries.
Asset Materials

How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →